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Eight quinoxalinone derivatives were synthesized and investigated for some neuropharmacological 
effects (analgesia, sedation, convulsion, anxiety, memory and psychosis) in mice and rats. In the CNS 
depressant activity, N,N-dibenzyl-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonamide is the most 
active, while the other compounds appear variously dose-dependent. Only three of the compounds 
showed anxiolytic effect, with N,N-dibenzyl-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonamide 
showing the highest activity at 2.5 mg/kg. At the dose of 30 mg/kg, 6-nitro-1,4-dihydroquinoxaline-2,3-
dione showed a better anxiolytic effect in mice than diazepam (dose: 1 mg/kg), while 1,2,3,4-tetrahydro-
quinoxaline-2,3-dione (dose: 25 mg/kg) showed a comparative effect to diazepam. 6-Chloro-1,4-
dihydro-quinoxaline-2,3-dione and N,N-dibenzyl-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonamide 
showed significant anticonvulsant action. None of the compounds showed any analgesic or antido-
paminergic effect. The LD50 (24 h) calculated for the compounds were between 74 and 160 mg/kg i.p. 
 






Quinoxalines, including their fused-ring derivatives, 
display diverse pharmacological activities.  For example, 
some display antibacterial (Badran et al., 2003; El-
Hawash et al., 1999; El-Gendy et al., 1995; Nasr, 2002; 
Refaat et al., 2004), antifungal (Kurasawa et al., 1986; 
Sanna et al., 1999), anticancer (Monge et al., 1995; 
Sanna et al., 1999; Carta et al., 2001), antimalarial 
(Crowther et al., 1949; Rangisetty et al., 2001), anti-
tubercular (Jaso et al., 2003), and antidepressant 
(Sarges et al., 1990) activities.  Also, some quinoxalin-2-
ones 1 and quinoxaline-2,3-diones 2 (Figure 1) have 
been reported to show antimicrobial (Ali et al., 2000; 
Obafemi and Akinpelu, 2005), novel, potent antithrom-
botic (Ries et al., 2003), anti-pain and anti-inflammatory 
(Wendt and Ledig, 1969; Warner and Luber, 1979; Su 
and Bock, 2005) activities. 




*Corresponding author. Tel: (234)8034753605.  E-mail: 
adeyemi01@yahoo.com. 
is the ionotropic receptors.  In this class is the 2-amino-3-
(3-hydroxy-5-methylisoxazol-4-yl) propanoic acid 
(AMPA), 3, receptors (Figure 1).  AMPA receptors have 
been found to be involved in both seizure initiation and 
seizure maintenance (Loscher, 1998; Rogawski and 
Donevan, 1999).  Therefore, inhibitors of AMPA receptor 
activity may be useful as neuroprotective agents.  Com-
pounds acting as AMPA antagonists are now generally 
known to be potentially useful for the prevention and 
treatment of a broad range of acute and chronic neurol-
ogical disorders (Chimirri et al., 1999). 
In the literature are described different series of AMPA 
receptor antagonists, one of which is based on the 
quinoxa-line-2,3-dione structure 2, which have high 
affinity and selectivity. Typical examples are 7-nitro-2,3-
dioxo-1,2,3,4-tetrahydroquinoxaline-6-carbonitrile 
(CNQX), 4; 6-(1H-imidazol-1-yl)-7-nitro-1,4-dihydroquino-




acid (Lu112313), 7; 6-nitro-2,3-dioxo-1,2,3,4-tetrahydrob- 
 
































enzo[f]quinoxaline-7-sulfonamide (NBQX), 8 and an 
analog of the 2,3-quinoxalinediones, 9-(1H-imidazol-1-yl)-
8-nitropyrazolo[1,5-c]quinazoline-2,5(3H,6H)-dione (Ro-
48-8587), 9 (Figure 2). Many of these compounds have 
been reported to exhibit anticonvulsant activity in animal 
models of epilepsy: NBQX (Loscher and Honack, 1994; 
Nordholm et al., 1997), YM90K (Kodama et al., 1999), 
Lu112313 (Loscher et al., 1999). 
In continuation of our studies on quinoxaline com-
pounds (Obafemi and Akinpelu, 2005), some simple 2,3-
quinoxalinediones, containing electron-donating and 
electron-withdrawing groups and two 2-quinoxalinones, 
with only one carbonyl functional group, were synthe-
sized and  screened for neuropharmacological activity in 
mice and rats (analgesia, sedation, convulsion, anxiety, 







Melting points were determined with open capillary tubes on a 
Gallenkamp (variable heater) melting point apparatus (uncorrec-
ted). Infrared spectra were recorded as KBr pellets on a Buck 
spectrometer. 1H- and 13C-NMR spectra were run on a Bruker-AC-
250 and JEOL-JNM-GX 400-MHz spectrometer (δ in ppm relative to 




Synthesis of 1, 2, 3, 4-tetrahydroquinoxaline-2,3-dione (10) 
 
A powdered mixture of oxalic acid dihydrate (5.0 g, 39.7 mmol) and 
1, 2-diaminobenzene (4.3 g, 39.8 mmol) was put in an open beaker 
and 1 mL of water added and mixed thoroughly.  The mixture was 
irradiated in a domestic microwave (MW) oven at an emitted power 
of 400 W for 3 min. 100 mL of water was added, followed by further 
irradiation for 1 min. to give a clear solution and then left to stand at 
room temperature to afford colorless needles of 10 (6.4 g, 99%).  
(m.p. > 340oC, Obafemi and Pfliederer, 1994) m.p. > 340oC).  Other 




Synthesis of 6-chloro-1, 4-dihydroquinoxaline-2,3-dione (11), 6-
methyl-1,4-dihydroquinoxaline-2,3-dione (12) and 6-nitro-1,4-
dihydroquinoxaline-2,3-dione (13). 
 
Compounds 11, 12 and 13 were prepared following the procedure 
described for compound 10. Quinoxalinedione 11 was obtained as 
ash-gray colored crystals (m.p. > 320oC), lit.(Obafemi and 





3046, 1695, 1390 cm-1; 1H NMR (400 MHz, DMSO-d6): δ 7.08 (s, 
3H, C (5)-H, C (7)-H, C (8)-H), 11.95 (s, br, 2H, 2NH, exchangeable 
with D2O).  MS: in m/z (rel. %): 196 (90), 168 (69), 140 (18), 113 
(20), 105 (100), 78 (28). 
Compounds 12 was obtained as white crystals (m.p. > 300oC, 
lit.(Obafemi and Pfleiderer, 2005) m.p. > 300oC) in 98% yield.  IR 
(KBr): νmax 3180, 2985, 1695 cm-1.  1H NMR (400 MHz, DMSO-d6): δ 
2.26 (s, 3H, CH3), 6.89 (d, 1H, C (8)-H), 6.94 (s, 1H, C (5)-H), 7.03 
(d, 1H, C (7)-H), 11.88 (s, 1H, NH, D2O exchangeable), 11.92 (s, 
1H, NH, D2O exchangeable).  MS: in m/z (rel. %): 176 (100), 148 
(72), 120 (50), 105 (47), 93 (47), 77 (46). 
Compound 13 was obtained as dark-brown crystals (m.p. > 
320oC) in 97% yield.  IR (KBr): νmax 3442 (w), 3050, 1690, 1535, 
1330 cm-1.  1H NMR (400 MHz, DMSO-d6): δ 7.15 (d, 1H, C (8)-H), 
7.82 – 7.89 (m, 2H, C (5)-H and C (7)-H), 12.15 (s, 1H, NH, D2O 
exchangeable), 12.36 (s, 1H, NH, D2O exchangeable).  13C NMR 
(50 MHz, DMSO-d6): δ 155.0 (C = 0), 154.6 (C = 0), 141.9, 131.4, 
125.8, 118.4, 115.3, 110.2 MS: 207 (M+).  Anal. Calc. for C8H5N3O4 
(207.1): C 46.39, H 2.43, N 20.29; found: C 46.21, H 2.50, N 20.13. 
 
 
Synthesis of 2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonyl 
chloride (14a) 
 
Pure and dry 10 (5.0 g, 30.9 mmol) was added in small portions to 
chlorosulfonic acid (21 mL, 10 mmol equiv.) at room temperature, 
after which the resulting mixture was heated at 110oC for 8 h.  The 
reaction mixture was cooled in ice and then poured into crushed ice 
to give white solid.  The product was filtered and washed three 
times with cold water and dried. The solid was recrystallized from 
dry toluene-acetone mixture to give white crystals of 2,3-dioxo-
1,2,3,4-tetrahydroquinoxaline-6-sulfonyl chloride 14a (m.p. 330oC 
(dec),) in 88% yield.  IR (KBr):  νmax 3380, 1680, 1355, 1140 cm-1. 
MS: in m/z (rel. %): 262 (5.3), 260 (14.0), 225 (48.1), 161 (100), 133 
(45.4), 105 (70.5), 78 (45.2), 51 (82.3).  Anal. Calc. for 
C8H5ClN2O4S (260.55): C 36.86, H 1.93, N 10.75; found: C 36.59, H 






2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonyl chloride (10.0 g, 
38.4 mmol) was dissolved in dry dimethylformamide (DMF) (200 
mL), followed by addition of dibenzylamine (15 mL, 78 mmol) and 
the resulting mixture was kept under stirring at room temperature 
for 10 h.  The reaction mixture was then poured into water (500 mL) 
to give a foamy white precipitate.  Recrystallization from aqueous 
ethanol gave white crystals of 14 (12.1 g, 75%) (m.p. > 300oC). IR 
(KBr). νmax 3330 (NH), 1682 (C=O), 1601, 1350, 1175 (SO2) cm-1. 
Anal. Calc. for C22H19N3O4S (421.47): C 62.69, H 4.54, N 9.97; 
Found: C 62.52, H 4.55, N 9.78. 
 
 
Synthesis of 2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonyl 
azide (15) 
 
2,3-Dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonyl chloride (14) (2.0 
g, 7.8 mmol) was dissolved in acetone (50 mL) and sodium azide 
(1.0 g, 15.4 mmol) in minimum amount of water was added in drops 
with continuous stirring. The mixture was stirred at room tempera-
ture for 8 h. Acetone was removed under reduced pressure follow-
ed by addition of water to give crude crystals of 15. Recrystalli-
zation from ethanol gave pure crystals of 15 (m.p. > 330 oC (dec.)) 
(Obafemi and Akinpelu. 1994)  m.p. > 330 oC) in 92 % yield.  IR 
(KBr): νmax 3320, 2150, 1690, 1360, 1165 cm-1.  1H NMR (400 MHz, 
DMSO-d6).   δ 7.95 – 7.19   (m, 3H, Ar-H),   12.74  (s, 1H,  NH, D2O 
 































































exchangeable), 12.92 (s, 1H, NH, D2O exchangeable). MS: in m/z 
(rel. %): 267 (100), 239 (17.0), 225 (18.3), 211 (6.0), 161 (10.0), 
133 (5.0), 105 (22.1).  Anal. Calc. for C8H5N5O4S (267.22): C 35.96, 
H 1.89, N 26.21 found: C 35.65, H 1.91, N 26.13. 
 
 
Synthesis of 1-acetyl-1H-indole-2, 3-dione (16a) 
 
Isatin (5.0 g, 34 mmol) was added to acetic anhydride (80 mL) and 
the mixture heated with continuous stirring at 90 – 100oC for 3 h.  
The reaction mixture was allowed to cool and then left in a fridge to 
give fine yellow crystals of 1-acetylisatin.  The product was filtered 
and the solvent was reduced to half to get more of the product (m.p. 
143 – 144oC) in 82 % yield.  IR (KBr):  νmax 1770, 1750, 1715, 1605, 
1466, 1387, 1338, 1280, 1265, 1168 cm-1. 1H NMR (200 MHz, 
DMSO-d6): δ 8.37 (d, 1H, C(7)-H), 7.30-7.73 (m, 3H, Ar-H), 2.70 (s, 
3H, CH3). 13C NMR (50 MHz, DMSO-d6): δ 180.1 (C=O), 169.5 
(C=O), 157.8 (C=O), 148.5 (Q), 138.7 (CH), 126,1 (CH), 125.1 
(CH), 119.1 (Q), 118.2 (CH), 26.2 (CH3). 
 
 
Conversion of 16a to N-[2-(3-Oxo-3, 4-dihydroquinoxalin-2-yl) 
phenyl] acetamide (16) 
 
1-acetylisatin (5.0 g, 26.4 mmol) was dissolved in ethanol (50 mL) 
in an open beaker.  The solution was then irradiated (pulsed) in a 
microwave (MW) oven for 2 min.  Ortho-phenylenediamine (2.9 g, 
26.8 mmol) in ethanol (30 mL) was added and the resulting mixture 
again irradiation in a MW oven (400 W) for 2 min (at 30 sec 
intervals) and the solution allowed to cool at room temperature, to 
give white crystals of 16 (m.p. 291 – 292oC (Wiedermannova et al., 
2000) m.p. 285 – 286oC) in 93 % yield.  IR (KBr): νmax 3260, 1675, 
1642, 1588, 1545, 1320 cm-1. 1H NMR (200 MHz, DMSO-d6):  δ 
1.95 (s, 3H, CH3), 7.10 – 7.83 (m, 8H, Ar-H), 9.78 (s, 1H, NH, D2O 
exchangeable), 12.50 (s, 1H, NH, D2O exchangeable).  13C NMR 
(DMSO-d6): δ 168.7 (C = 0), 157.6 (C = 0), 155 (Q), 137.5 (Q), 
133.0 (Q), 132.7 (Q), 131.4 (CH), 130.9 (CH) 130.2 (CH), 129.2 
(CH), 128.4 (Q), 123.9 (CH), 123.7 (CH), 115.8 (CH), 24.4 (CH3).  
Anal. Calc. for C16H13N3O2 (279.29): C 68.81, H 4.69, N 15.05; 
Found: C 68.72, H 4.66, N 15.00.  
 
 
Synthesis of 3-(2-aminophenyl) quinoxalin-2(1H)-one (17) 
 
Compound 16 (5.0 g, 17.9 mmol) was dissolved in 50% aqueous 
ethanol (50 mL) and KOH (5.0 g) was added and the reaction 
mixture was heated to reflux with stirring for 4 h.  The resulting 
solution was concentrated, using a rotatory evaporator under 
vacuum, to half its volume and then acidified with acetic acid.  The 
solution obtained was left to stand to give yellow crystals of 17 
(m.p. 258 – 260oC, lit. (Wiedermannova et al., 2000) m.p. 261-
262oC ). IR (KBr): νmax 3420 (NH), 1680 (C=O), 1630, 1580 cm-1. 
Anal. Calc. for C14H11N3O (237.26): C 70.87, H 4.67, N 17.71; 
Found: C70.68, H 4.60, N 17.56.  
 






Wister rats (180–195 g) of both sex, and albino mice of both sex 
(18–27 g) (Vom strain; National Veterinary Research Institute, Vom, 
Nigeria) were used. All the animals were bred and housed in well lit 
and aerated room in the Animal House, Faculty of Pharmacy, 
Obafemi Awolowo University, Ile-Ife according to standard animal 
care protocols. All animals had free access to drinking water and 
standard commercial diet (Guinea Feeds Brand, Bendel Feeds and 
Flour Mills Ltd, Ewu, Nigeria). The cages were cleaned regularly 





The drugs used for the experiments in this report are diazepam 
(Roche, Basel Switzerland), phenobarbitone sodium (Sigma 
Chemical Co, St Louis, USA), 1, 5-pentamethylenetetrazole 
(Aldrich, Milwaukee, USA), quinoxalinone derivatives strychnine 
HCL (BDH Chemical Ltd, England). All drugs were administered 
dissolved in normal saline and/or dimethyl sulphoxide (DMSO) on 
each day of the experiment. 
 
 
LD50 determination in mice 
 
The method described by Locke (1983) was used in determining 
LD50, which is the index of acute toxicity. In this method, animals 
(mice) were treated with each of the eight quinoxalinone derivatives 
after 5 days of adaptation to the laboratory. Each compound was 
administered at ten different doses- 20, 40, 60, 80, 100, 120, 140, 
160, 180 and 200 mg/kg via the intraperitoneal rout (n=10 for each 
dose level). The mice were observed hourly for the first 8 h and 
thereafter six hourly for 24 h and continued once a day up to 14 
days (Wafai and Mehta, 1986). Number of deaths was recorded. 
The LD50 was calculated after 24 h using the arithmetic method of 
Spearman-Karber (Hayes, 1989) and the results were validated by 
an internet hosted computer program of the United States 
Environmental Protection Agency (USEPA)-Probit Analysis Prog-




Novelty-induced behaviours in mice 
 
Novelty-induced behaviours were assessed and evaluated by the 
method previously described by Ajayi and Ukponmwan (1994). The 
behaviours scored were rearing, line crossing, grooming, face 
wash, genital licking, stretching, urination and defecation; all were 
summed as total locomotor activity. The animals were placed 
directly from home cages into an opaque plexiglas observation 
cage (45 x 25 x 25 cm) with only one side transparent for 
observation. All animals were observed and assessed singly in the 
plexiglas cage, after the administration of the test drugs or normal 
saline. Each animal was used only once, with the plexiglas cleaned 
with 70% alcohol after each assessment to remove olfactory cue 
from one animal to the other (Brown et al., 1999). The time of the 
experiments was kept constant (9a.m – 4 p.m. daily) to avoid 
changes in biological rhythm (Siquiera et al., 1998). The laboratory 
was brightly lit, with an ambient temperature of 27± 2oC. 
The frequency of each of the episodic behaviours was quantified 
by using a counter and a timer. The total frequency was summed 
up for each animal and totaled for the 30 minutes of observation 
time. Each of the test compounds (10-17) was injected intraperito- 
neally to mice and the effect on the total activity was compared to 





Anticonvulsant effect in mice 
 
The method of Soaje-Echaque and Lim was used. Mice were 
divided into different treatment groups. The test compounds 10-17 
(20-100 mg/kg) were administered i.p to the animals, while 20 
mg/kg phenobarbitone was used as a standard anticonvulsant drug 
(Siqueira et al., 1998). Control animals received an equal volume of 
saline (10 ml/kg). After 30 min 1, 5-pentamethylenetetrazol (80 
mg/kg i.p) was administered to all animals. The percentage of 
animals protected (not showing convulsion within 60 min after 1,5-
pentamethylenetetrazol (80 mg/kg-i.p) injection) was recorded 
(Siqueira et al., 1998). Similarly, strychnine (2 mg/kg i.p) was 
administered to another set of animals to induce convulsion and the 
protection offered by the test compounds 10-17 was also recorded 
 
 
Anxiolytic effect in mice 
 
Anxiety state was examined in mice using the elevated plus-maze 
model (Pellow et al., 1985; Handley and Mithani, 1984). The use of 
the elevated plus-maze as a model for testing anxiolytic effect of 
candidate drugs was validated in mice by Lister in 1987 (Lister, 
1987). The test is based on the natural aversion of rodents for open 
spaces and heights, and utilizes an elevated plus-maze with two 
open and two closed arms. The plus-maze was made of wood and 
consisted of two open arms 30 × 5 cm. and two enclosed arms 30 × 
5 × 15 cm. The arms extended from a central platform 5 × 5 cm. 
The open arms, the central platform and the floor of the closed 
arms were painted black. The apparatus was mounted on a 
wooden base, raising it 38.5 cm. above the floor. The open arms 
contained a slight ledge 4 mm high, to prevent the mice from 
slipping and falling off the edge. To eliminate any lingering olfactory 
cues, the apparatus was cleaned between each examination using 
70% ethyl alcohol. Each trial was recorded for 5 min with the 
following behaviours scored: 
 
(a) open arm entries 
(b) closed arm entries 
(c) time spent in the open arm 
(d) time spent in the closed arm  
 
The index of open arm avoidance, interpreted as level of anxiety 
(Trullas and Skolnick, 1993) was calculated as: 
 
[100 – (% time on open arm + % entries into open arms /2)] 
 
The effects of the test compounds 10-17 on anxiety in mice were 
compared with the effect of the anxiolytic dose (1 mg/kg, i.p.) of 
diazepam (Abdel-Barry and Al-Hakeim, 2000), a standard 
antianxiety drug (Haefely, 1984). Doses of the test compounds 
which did not affect motor coordination were used in the 
investigation of the anxiolytic potential of the test compounds 
(Reddy and Kulkarni, 1997). Mice of both sexes (20-27 g), naive to 
the apparatus and treatments were used for all the experiments and 
each mouse was used only once. Each mouse was placed in the 
center of the open arms after 25 min of intraperitoneal injection of 
the test compounds, reference drug or normal saline and the 
observation was made for 5 min (Lister, 1987, 1990; Trullas and 





The method of Siqueira et al., (1998) was used in determining the 
effect of the test compounds on amphetamine-induced stereotypy. 
Mice were allowed a minimum of 30 min to acclimatize to the 






were given 30 min before (dl)-amphetamine (35 mg/kg, i.p). Each 
mouse was individually observed for 2 min in observation cages (45 
x 25 x 25 cm) at 10, 20, 30 and 45 min after (d, l) – amphetamine. 
Stereotyped behavior was scored as follows: Complete absence of 
stereotyped behaviour (0); presence of stereotyped movements of 
the head and intermittent sniffing (1); sniffing and chewing (2), 
chewing and intense licking (3). The assessment was rated by a 





The method of Siqueira et al. (1998) was used in determining the 
effect of the test extracts on the apomorphine induced stereotypy. 
Mice were allowed a minimum of 30 min to acclimatize to the 
observation cages prior to the experiments. Test drugs were given 
30 min before apomorphine (35 mg/kg, i.p). Each mouse was 
individually observed for 2 min in observation cages (45 x 25 x 25 
cm) at 10, 20, 30 and 45 min after apomorphine. Stereotyped 
behavior was scored as follows: Complete absence of stereotyped 
behaviour (0); presence of stereotyped movements of the head and 
intermittent sniffing (1); sniffing and chewing (2), chewing and 
intense licking (3). The assessment was rated by a skilled indepen-
dent observer who was blind to the treatment. 
 
 
Pain threshold (hot plate, 51°C) in mice 
 
The hot plate test is a good model for assessing candidate drugs 
for analgesic activity (Le Bars et al., 2001; Vogel, 2002). It consists 
of introducing the animal into an open ended cylindrical space with 
a floor consisting of a metallic plate that is heated by a thermode 
(Bibby model, Hotplate SH3, Stuart Scientific, U.K.). The experi-
mental protocol consists of dividing animals into treatment dose 
groups of at least five mice per group: 
 
1. Group one mice were acutely treated with the test compounds 
10-8-17 alone. 




Pain threshold (paw pressure) in rats 
 
Pain sensitivity to noxious paw pressure was assessed in rats (120-
130 g) by the method of Randall and Selitto (1957) as modified by 
Ukponmwan et al (1986) Nociception was measured using the 
analgesiometer (Analgy Meter, Number 15877, UgoBasile, Milan, 
Italy) at 0, 30, 60, and 120 min after the administration of doses of 
test compounds 10-17. Analgesia was expressed as analgesio-
metric scores (AMS) g mm-2 pressure (Ukponmwan et al, 1986). 
The cut off value was measured by a squeak or paw withdrawal. 
Animals scoring above 150 g mm-2 during control testing were not 
used for further experimentation. The experimental protocol 
employed in this study is as follows. Rats were divided into groups 
of at least 5 rats each:  
 
1. Animals in group one were treated acutely with physiological  
saline (SAL 10 ml/kg, i.p.) 
2. A second group of rats received the test compounds 10-17 and 





Results of the experiments and observations are expressed as 
mean ± standard error of mean (s.e.m) in this report. The signifi-
cance of differences between  groups  was  determined  using  one-  




way analysis of variance (ANOVA), followed by post hoc analysis 
using the Student-Newman-Keuls test. In the determination of 
median lethal dose (LD50), the Spearman-Karber arithmetic method 
was used. The results were validated by a computer programme 
developed by the United States Environmental Protection Agency 
(USEPA)-Probit Analysis Program for the Determination of LC/EC 
values, Version 1.5 (2004). In all the observations, statistical 
significance was accepted at p values less than or equal to 0.001. 
In all these statistical determinations, a computer programme-the 





Synthesis of the compounds 
 
The 2,3-quinoxalinediones 10-13 were synthesized by 
the reaction of appropriate benzene-1,2-diamines with 
oxalic acid dihydrate under microwave irradiation 
(Obafemi and Akinpelu, 2005). Compound 10 was 
chlorosulfonated by its reaction with excess chloros-
ulfonic acid at about 110 oC to give 2,3-dioxo-1,2,3,4-
tetrahydroquinoxaline-6-sulfonyl chloride 14a. The 
reaction of the quinoxalinesulfonyl chloride with dibenzy-
amine gave N,N-dibenzyl-2,3-dioxo-1,2,3,4-tetrahydroq-
uinoxaline-6-sulfonamide, 14. In a similar manner, 
compound 14a was allowed to react with sodium azide to 
give 2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonyl 
azide 15 (Figure 3). 
The quinoxalinone derivative 16 was synthesized 
starting from 1H-indole-2,3-dione (isatin). Isatin was 
allowed to react with acetic anhydride to give 1-acetyl-
1H-indole-2,3-dione 16a, which was reacted with 
benzene-1,2-diamine in ethanol, under microwave irrad-
iation, where a ring opening-ring closure steps had 
proceeded to give N-[2-(3-oxo-3,4-dihydroquinoxaline-2-
yl) phenyl] acetamide 16. Compound 16 was subjected to 
hydrolysis, using KOH in aqueous ethanol, to yield 3-(2-
aminophenyl) quinoxalin-2-one 17 (Figure 4). 
 
 
Calculated LD50 for the test compounds 
 
The LD50 calculated for each of the test compounds is as 
shown in Table 1. Compound 14 showed the lowest LD50 
of 74 mg/kg, i.p while compound 12 showed the highest 
LD50 of 160 mg/kg, i.p, with other compounds having LD50 
values comparable to compound 12. 
 
 
Total locomotor activity in mice 
 
The entire test compounds (10-17) exhibited significant 
(p< 0.001) inhibition of total locomotor activity in mice in a 
dose-dependent manner (Table 1). The maximum dose 
(100 mg/kg, i.p.) that induced maximal inhibition of total 
locomotor activity in mice is almost the same for all the 
compounds except compound 14 which exhibited 
maximal inhibition at 40 mg/kg, i.p.  
 




































10:          H
11:          Cl
12:          CH3
13:          NO2













Anticonvulsant activity in mice 
 
The result of the anticonvulsant test of the synthesized 
compounds is as shown in Table 3. Compound 14 pro-
tected the mice against both 1,5-pentamethyle-netetrazol 
and strychnine-induced convulsions, and the effect was 
superior to the protection offered by 20 mg/kg i.p. 
phenobarbitone sodium employed as the standard 
anticonvulsant drug (100% Vs 90%, respectively). 
Compound 11 protected mice from the convulsive action 
of 1,5-pentamethylenetetrazol only and not from the 
convulsion induced by strychnine and the protection was 
comparable to that produced by phenobarbitone (20 
mg/kg, i.p.). The other compounds (10, 12, 13, 15, 16 
and 17) did not show any anticonvulsant effect against 
the two convulsive agents. 
 
 
Anxiolytic effect in mice 
 
Only compounds 10, 13, and 14 exhibited anxiolytic 
effect by inducing low index of open arm avoidance in 
mice in an elevated plus maze model of anxiety (Table 
2). Compounds 13 and 14 showed anxiolytic effect in 
mice that was superior to the effect produced by 
diazepam (1 mg/kg, i.p.) while compound 10 exhibited 
anxiolytic effect comparable to diazepam. The other 




Analgesic and antidopaminergic effects 
 
Experiments with amphetamine and apomorphine-
induced stereotyped behaviour in mice, pain threshold 
(hot plate, 51°C) in mice and pain threshold (paw 
pressure) in rats were all negative for the entire 





All the quinoxalinone derivatives (10-17) have been found 
to have varying degrees of acute toxicity in mice. The 
order of acute toxicity of the quinoxalinone derivatives 
(14>>10~11~13~15~16~17>12) indicates that compound 
14 is the most toxic and 12 the least toxic. The only struc- 
 





































Table 1. Effect of compounds (10-17) on total locomotor activity in mice and the LD50 values of the compounds. 
 
Treatment Total locomotor activity (n=5)  
Dose 
Drug 
20 mg/kg,i.p. 40 mg/kg,i.p. 80 mg/kg,i.p. 100  mg/kg,i.p. LD50 
Normal saline (10 ml/kg, i.p.) 120±5.0     
10 111±4.7 82±3.7* 60±1.5* 53±4.0* 144 
11 98±4.0* 85±2.0* 79±2.5* 39±3.5* 150 
12 100±4.0* 80±1.5* 66±1.8* 30±3.3* 160 
13 118±6.3 65±2.6* 61±1.6* 54±3.0* 154 
15 110±5.0 85±3.0* 71±1.8* 65±3.2* 150 
16 123±6.0 85±3.6* 41±4.8* 26±3.8* 152 
17 105±4.2* 66±5.1* 23±3.0* 16±2.0* 149 










*indicates significant difference from the normal saline control treatment (p<0.001; Student-Newman-Keul post hoc 
test). 
Note the difference in effective doses for compound 14 (in bold). 





tural difference between the most toxic and the least toxic 
being that compound 12 has an electron-donating methyl 
group (CH3) at position 6 , while 14 has an electron-
withdrawing N,N-dibenzylsulfonamido group 
((PhCH2)2NSO2-) at position 6. 
From the total locomotor activity test, all the quinoxali-
none derivatives (10-17) have been found to have strong 
sedative effect in mice, in the order 
(14>17>16>12>11>10>15). Compound 14 exhibited the 
most sedative effect (~ 5 at 40 mg/kg,i.p.), indicating that 
a dibenzylsulfonamido group ((PhCH2)2NSO2-) at position 
6 is beneficial in exhibiting sedative property. This can be 
inferred, for example, when compound 14 is compared 
with  15 which carries an azidosulfonyl group (N3SO2-) at 
 




Table 2. Effect of compounds (10-17) on the frequency of arm entries and time spent in the arms of an elevated plus maze in 
mice. 
 
Treatment Number of entries 
into arms 
Time spent in each 
arm 










Normal saline (10 
ml/kg, i.p.) 
5±1.0 16±3.1 50±4.0 221±7.0 22.6 23 77.2 
10 (25 mg/kg, i.p.) 13±3.2 5.0±1.0 189±8.2 100±6.2 63.0 72.2 32.4* 
11 (10mg/kg, i.p.) 4±1.1 12±2.1 22±3.1 265±7.0 7.3 25.0 83.9 
12 (10 mg/kg, i.p.) 3±1.0 12±3.0 505±4.0 238±11.0 16.8 20.0 81.6 
13 (30 mg/kg, i.p.) 15±2.0 3±1.0 171±9.0 119±5.0 57.0 83.3 29.9* 
14 (2.5 mg/kg, i.p.) 17±3.0 4±2.0 202±8.0 94±7.3 67.3 81.0 25.9* 
15 (30 mg/kg, i.p.)  5±2.1 14±3.0 55±3.6 225±8.2 18.3 26.3 77.7 
16 (30 mg/kg, i.p.) 6±1.1 15±2.0 25±5.2 254±9.0 8.3 28.6 81.6 
17 (10 mg/kg, i.p.) 4±1.2 15±3.0 59±7.1 230±6.2 19.7 21.1 79.6 
Diazepam (1 mg/kg 
i.p.) 
14±2.0 3±1.0 160±5.0 110±4.0 53.3 82.4 32.2* 
 
* indicates significant difference from the normal saline control treatment (p<0.05; SNK post hoc test). Number of mice per treatment 
was 5. Note that anxiolytic doses are lower than sedative doses to avoid affecting motor coordination in the animals. Test compounds 




Table 3. Anticonvulsant screening of synthesized compounds.  
 
Protection (%) at 60 min after Drug treatment Dose mg/kg I.P. 
Leptazol 80 mg/kg i.p. Strychnine 2.0 mg/kg i.p. 
Control (saline) 10 mg/kg 0 0 
10 100 0 0 
11 100 100 0 
12 100 0 0 
13 100 0 0 
14 25 100 100 
15 100 0 0 
16 100 0 0 
17 100 0 0 




position 6 but showed only a locomotor activity of ~65 (at 
maximum dose of 100mg/kg,i.p). In addition, compounds 
16 and 17 exhibited high sedative effects suggesting that 
a 2-aminophenyl group at position 3 of a quinoxalinone 
ring is also beneficial for such activity. 
Only compounds 11 and 14 possessed anticonvulsant 
activity. While compound 11 was effective against 1.5-
pentamethylenetetrazol, compound 14 was effective 
against both 1,5-petamethylenetetrazol and strychnine. 
This suggests that while compound 11 is acting on the 
GABAergic system to offer neuroprotection against the 
induced convulsion, compound 14  appeared to possess 
both GABAergic and glycinergic effect due to its 
protection of the animals from strychnine induced 
convulsion (Olayiwola, 2005). It is interesting to note that 
other compounds (10, 12, 13, 15-17) did not protect the 
mice against the induced convulsion, showing that only 
the chloro (Cl) functional group at position 6 and the N-N-
dibenzylsulfonamido group are essential for neuro-
protection against the induced seizures. In addition, the 
observed good activity of the dibenzylsulfonamdoquin-
oxalinedione 14 is in agreement with the binding site 
hypothesis of Dimmock (Dimmock and Baker, 1994) and 
Pandeya (Pandeya et al, 2000), in some aryl semicarb-
azones, in which (a) an aryl hydrophobic binding site 
(AH), (b) hydrogen-bonding site (HBD) and (c) an 
electron donor site (D) are required for anticonvulsant 
activity. In our series of compounds, the active compound 
14 possess all the essential requirements for anticonv-
ulsant activity as proposed by Dimmock and other 
workers (Figure 5). The clinically available anticonvulsant 
compounds-diazepam (18) and phenobarbital (19) have 
two or three of these characteristics, respectively, that 


















Figure 5. Structure of 14 showing the locations considered to be 
hydrophobic binding area (AH), hydrogen bonding site (HBD) and 





















Figure 6. Clinically available anticonvulsant compounds, diazepam (18) 




Furthermore, AMPA receptors agonists, such as 
compound 3, have been implicated in seizures induced in 
experimental animal. (Loscher, 1998; Rogawski and 
Donevan, 1999). Compounds 4-9 have high affinity and 
selectivity for the AMPA receptors as antagonists and 
accordingly exhibited anticonvulsant effect (Loscher and 
Honack, 1994; Nordholm et al., 1997; Kodama et al., 
1999; Loscher et al., 1999). Compounds 11 and 14 which 
are quinoxalinone derivatives, just like compounds 4-8, 
showed anticonvulsant activity. The strong anticonvulsant 
effect of 14 may reside in its large hydrophobic group 
which confers strong ability to cross the blood-brain 
barrier, and the electron donating action of the chloro 
group on 11 might be responsible for the anticonvulsant 
effect observed in 11. It is therefore interesting to note 
that the anticonvulsant effect of 14 might be due to 
stimulation of a repertoire of receptors which include 
GABA, GABA-benzodiazepine, glycine and antagonism 
of AMPA receptors, while the anticonvulsant effect of 11 
might be due to combination of glycine receptors stimul-
ation and AMPA receptors antagonism. 
Anxiolytic effects were observed in compounds 10, 13 




and 14, at the doses selected (which were generally 
lower than the sedative doses of the compounds to 
prevent motor incordination in the mice). It is interesting 
that while the anxiolytic effect induced by compound 10 
was comparable to that of diazepam, those due to com-
pounds 13 and 14 were superior to the anxiolytic effect of 
diazepam (Table 2). The functional groups present in 11, 
12, 15, 16 and 17 were not able to confer anxiolytic 
effect, even though they all showed sedative effects. This 
observation suggests that anxiolytic effect of compounds 
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